Navigation Links
Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis

d A.G.G. Turpie, M.D., EXPERT's principal investigator and Professor of Medicine at McMaster University in Hamilton, Ontario. "We have long awaited a new generation of oral anticoagulants, and Portola has a promising compound with compelling drug characteristics resulting in consistent activity without the need for dose adjustment or monitoring. We will be closely following PRT054021 as it progresses into late-stage clinical trials."

Dr. Turpie discussed these data today in a poster session titled "Evaluation of the Factor Xa (fXA) Inhibitor, PRT054021 (PRT021), Against Enoxaparin in a Randomized Trial for the Prevention of Venous Thromboembolic Events after Total Knee Replacement (EXPERT)."

"We are very pleased by the EXPERT results, as PRT054021's clinical performance compared favorably to recent studies of enoxaparin for the prevention of VTE," said Dan Gretler, M.D., Portola's vice president of clinical and regulatory affairs. "We look forward to initiating our Phase III trials to further study our hypothesis that our oral, once-daily anticoagulant with superior pharmaceutical properties, including a relatively flat peak to trough concentration ratio, will lead to better outcomes for patients."

About EXPERT

EXPERT (Evaluation of the Factor Xa Inhibitor, PRT054021, against Enoxaparin in a Randomized Trial for the Prevention of Venous Thromboembolic Events after Unilateral Total Knee Replacement) randomized 215 U.S. and Canadian patients undergoing TKR surgery in a 2:2:1 ratio to receive 15 mg of PRT054021, 40 mg of PRT054021, or 30 mg of Lovenox(R) (enoxaparin) for 10-14 days. PRT054021 was given orally twice a day, and enoxaparin was given twice a day as a subcutaneous injection. The primary efficacy endpoint was the incidence of VTE through day 10-14 measured by venography. Safety endpoints included the incidence of major and clinically significant non-major bleeds through the day after venography. All efficacy and safety endpoints w
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/30/2014)... MAHWAH, N.J. , July 30, 2014 Stryker brand ... playing this week at the 3M Championship Champions Tour event near ... Twin Cities, in Blaine . Stryker is the ... Tour. Starting Friday, August 1 st through ... the Stryker Mobility Zone; an on-site joint health destination located in ...
(Date:7/30/2014)... 30, 2014 Cynosure, Inc. (NASDAQ: ... treatments for non-invasive and minimally invasive applications, today announced that ... Operating Officer and Chief Financial Officer Timothy W. Baker ... Baker, 53, will continue to serve as CFO and will ... who remains Chairman and Chief Executive Officer. ...
(Date:7/30/2014)... SANTA CLARA, Calif. , July 30, 2014 /PRNewswire/ ... innovation economy, released a study today that ... venture-backed biopharma and medical device companies.  According to the ... healthcare saw the biggest potential returns since SVB started ... the year of the IPO.  Built on solid healthcare ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3
... 2011 Hypoxic (oxygen-deprived) tumor cells usually resist radiation ... cancer. Researcher Xin Chen, Ph.D. believes that ... with malignant solid tumors in areas such as the ... an assistant professor in the Department Radiation Oncology at ...
... July 26, 2011 SCOLR Pharma, Inc. (OTC: SCLR) today ... ended June 30, 2011 and also provided updates on a ... the Company issued an aggregate of $1.2 million principal amount ... "Debentures") in a private offering of Debentures. The Company intends ...
Cached Medicine Technology:Arkansas Researcher is Exploring MR-Guided Focused Ultrasound as an Adjuvant Therapy to Radiation 2Arkansas Researcher is Exploring MR-Guided Focused Ultrasound as an Adjuvant Therapy to Radiation 3SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results 2SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results 3SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results 4SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results 5SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results 6
(Date:7/30/2014)... York (PRWEB) July 30, 2014 The ... brain bleeding has filed a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ... blood thinner, Bernstein Liebhard LLP reports. According to the ... the District of Vermont on July 25th, the decedent ... he suffered an irreversible brain bleed that ultimately led ...
(Date:7/30/2014)... The phrase "we caught it early" is possibly the ... of a cancer diagnosis. Combating cancer in its earliest ... part of the body, gives patients the best chances ... prostate and other forms of cancer are touted for ... recommend cancer screenings as a precautionary measure, especially for ...
(Date:7/30/2014)... VA (PRWEB) July 30, 2014 The ... 2014-2015 Board of Directors. Sandra Aiken Chack will serve ... month at the EDNF 2014 Annual Learning Conference in ... Foundation has an ambitious agenda ahead of us. From ... Care & Research at the Greater Baltimore Medical Center ...
(Date:7/30/2014)... Children’s Hospital of Michigan Foundation and Kohl’s ... p.m. to 7 p.m. Wednesday, August 6 at the ... MI 48152). The event will feature Detroit Red Wings ... snacks and local public safety officials. Kohl’s will present ... Michigan Foundation. , The gift supports Kohl’s Injury ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Frozen shoulder (Adhesive ... more likely to develop this nasty condition which occurs most ... and can last up to two and half years if ... frozen shoulder, and with good reason: it can render your ... — that is, if you aren't in too much pain ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4
... accidents were the biggest killers. Now it appears that the ... to the fatalities caused by road accidents. , ... University of Edinburgh, has provided statistics which demonstrates the increase ... annually; in contrast, MRSA cases had dropped by 4.3 per ...
... International Myeloma Foundation (IMF) - supporting research and ... families, researchers and physicians// - today said physicians ... dexamethasone when treating patients with multiple myeloma. ... standard therapy for the treatment of myeloma alone ...
... of lung cancer among people with chronic obstructive pulmonary ... corticosteroids are medications that are approved for use in ... ,How inhaled corticosteroids work in asthma is still ... reduce inflammation in the airways thereby improving symptoms associated ...
... in developing nations is undermining essential health services, including ... Organization Director-General Margaret Chan said on Tuesday in Singapore ... ,Thousands of health care professionals have left their ... jobs in wealthier countries, Reuters reports. ,According ...
... clinical disease progression and death in HIV-1-infected women ... in the Journal of Acquired Immune Deficiency Syndromes. ... HIV-infected Tanzanian women and recommends screening for depression ... comprehensive HIV care. ,There is increasing ...
... has signed an exclusive worldwide Collaborative Research and ... delivery technologies, including the Medidur technology in ophthalmic ... agreement, pSivida will receive up to $155 million ... ,Pfizer will have an exclusive license to ...
Cached Medicine News:Health News:New Clinical Trial Results Could Improve Survival for Myeloma Patients 2Health News:New Clinical Trial Results Could Improve Survival for Myeloma Patients 3Health News:Inhaled Corticosteroids may Reduce Lung Cancer Risk 2Health News:Depression Increases the Risk of Disease Progression and Death in HIV-positive Women 2
Cross action, round handle, maximum opening 2.8 mm....
Irrigating nucleus chopper, tip angled 30 to side wedge shaped inferior edge with blunt tip and front notch for engaging iris end opening, 19 gauge. For use in the right hand....
Small pupil irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip and front notch, for engaging the iris, 0.6 mm dual sideports, 20 gauge....
Irrigating nucleus chopper, 1.5 mm long wedge-shaped, inferior edge with round end, 0.6 mm dual sideports 20 gauge....
Medicine Products: